We are a physics driven drug discovery company. Using advanced simulation software and AI-enhanced medicinal chemistry, we develop novel drug candidates and innovative mode of action against challenging targets. We design our drug candidates atom by atom to optimize their efficiency and their specificity with a favorable safety profile at unprecedented speed.
We build upon more than 30 years of R&D awarded by the most prestigious prizes such as 2 ERC grants and the ATOS Fourier prize. We spun-off from leading research institutions in France and in the USA : CNAM, CNRS, University of Texas at Austin, Sorbonne University and Washington University, in Saint Louis and we are based in Paris, at the very heart of “Le quartier Latin” and in Boston.
We are supported by three major deeptech investment funds Quantonation, Xange and Omnes Capital. In less than 18 months, we have built an impressive track record of awards such as the EIC accelerator thanks to our team and the technology.
We are embarking the most brilliant minds in theory, methods, software and drug design from both sides of the Atlantic to deliver on our mission and improve people’s lives.